Amivantamab, an EGFR-MET bispecific monoclonal antibody, was FDA-approved in May 2021 for the treatment of adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations and is showing promising results [145]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.